Synexus Clinical Research PLC
18 September 2006
Synexus Clinical Research plc appoints
Paul McCluskey as Chief Financial Officer
Synexus Clinical Research plc ("Synexus") the international organisation
providing patient recruitment to the global clinical trials industry, is pleased
to announce the appointment of Paul McCluskey as Chief Financial Officer with
immediate effect.
Most recently, Paul, aged 42, was the European Managing Director of the formerly
autonomous subsidiary of RHM plc, RHM Ingredients Ltd, which was acquired by
private American owners. He is a fellow of the Institute of Chartered
Accountants and previously held finance positions with BAE Systems plc and
GlaxoSmithKline plc. Paul succeeds Chris Neilson, the previous Finance Director
of Synexus, who is leaving the company to pursue other opportunities. The board
would like to thank Chris and wish him well for the future.
Michael Fort, CEO of Synexus, commented
"We are delighted to have attracted Paul to Synexus. He has considerable
experience of managing acquisitions and integrating those operations into a
unified business. Synexus' strategy is to build, through targeted acquisitions,
an international patient recruitment capability to manage large numbers of
clinical trial patients for pharmaceutical clients. Paul's experience in
integrating businesses, systems and management teams will strengthen our overall
capabilities as we continue to expand."
The following information is given in respect of Paul McCluskey as required by
Schedule 2 paragraph (g) of the AIM Rules.
Directorships held within the previous five years
Newly Weds Foods (Europe) Limited
Newly Weds Foods Limited
NWF Europe Limited
RHM Ingredients Limted
Press enquiries:
Synexus Clinical Research plc Tel: +44 (0)1257 230 723
Michael Fort, Chief Executive
Biddicks - Financial Public Relations Tel: +44 (0)20 7448 1000
Zoe Biddick
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.